Distinct gene signatures define the epithelial cell features of mucinous appendiceal neoplasms and pseudomyxoma

Carlos Ayala1, Anuja Sathe2, Xiangqi Bai2

  • 1Division of Surgical Oncology, Department of Surgery, Stanford University, Stanford, CA, United States.

Frontiers in Genetics
|February 28, 2025
PubMed
Abstract

Insights

This study reveals distinct gene signatures in appendiceal mucinous neoplasms (AMN) and pseudomyxoma peritonei (PMP) tumors. Understanding these cellular features and tumor heterogeneity may lead to new treatment targets for these rare gastrointestinal cancers.

Area of Science:

  • Gastrointestinal Oncology
  • Cancer Cell Biology
  • Genomics

Background:

  • Appendiceal mucinous neoplasms (AMN) are rare gastrointestinal tumors.
  • AMN can lead to pseudomyxoma peritonei (PMP), a widespread abdominal disease with a poor prognosis.
  • The cellular origins, differentiation, and progression of AMN and PMP remain poorly understood.

Purpose of the Study:

  • To characterize the cellular features and heterogeneity of AMN and PMP.
  • To identify specific gene expression signatures in AMN and PMP tumor cells.
  • To uncover potential novel therapeutic targets and understand treatment resistance mechanisms.

Main Methods:

  • Single-cell RNA-sequencing of AMNs, PMPs, and matched normal tissues.
  • Validation using immunohistochemistry and mass spectrometry.
  • Analysis of gene expression data from an independent cohort of PMP tumors.

Main Results:

  • Identification of previously unknown cellular features and heterogeneity in AMN and PMP.
  • Discovery of tumor-specific gene expression signatures, including goblet cell differentiation and mucin production.
  • Metastatic PMP cells exhibit distinct signatures related to lipid metabolism, inflammation, and signaling pathways (JAK-STAT, RAS).
  • Observed clonal heterogeneity within individual PMP tumors and between metastases from the same patient.

Conclusions:

  • Defined tumor cell gene signatures for AMN and PMP, overcoming technical challenges.
  • Provided insights into tumor origin, differentiation, and identified potential novel treatment targets.
  • Highlighted tumor heterogeneity as a significant factor contributing to treatment resistance.